CYP11B2 -344T/C gene polymorphism and blood pressure in patients with acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 12, 2006, Pages 5008-5012

  Mulatero, Paolo ^a,e   Veglio, Franco ^a   Maffei, Pietro ^c   Bondanelli, Marta ^d   Bovio, Silvia ^b   Daffara, Fulvia ^b   Leotta, Giannina ^a   Angeli, Alberto ^b   Calvo, Chiara ^a   Martini, Chiara ^c   Degli Uberti, Ettore C ^d   Terzolo, Massimo ^b  

^a Division of Internal Medicine and Hypertension   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e Ospedale San Vito   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE SYNTHASE; ALPHA ADDUCIN; DIPEPTIDYL CARBOXYPEPTIDASE; SODIUM;

ACROMEGALY; ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

EID: 33845498855     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-0049     Document Type: Article

References (42)

1. Melmed S 1990 Acromegaly. N Engl J Med 322:966-977
2. Colao A, Lombardi G 1998 Growth-hormone and prolactin excess. Lancet 352:1455-1461
3. Orme SM, McNally RJ, Cartwright RA, Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730-2734
4. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102-152
5. Holdaway IM, Rajasoorya RC, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
6. Gordon DA, Hill FM, Ezrin C 1962 Acromegaly: a review of 100 cases. Can Med Assoc J 87:1106-1109
7. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG 1994 Acromegaly. Clinical and biochemical features in 500 patients. Medicine 73: 233-240
8. Bondanelli M, Ambrosio MR, degli Uberti EC 2001 Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 4:239-249
9. Pietrobelli DJ, Akopian M, Olivieri AO, Renauld A, Garrido D, Artese R, Feldstein CA 2001 Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values. J Hum Hypertens 15:601-605
10. Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S, Lomardi G, Colao A 2005 Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) 63:470-476
11. Davies DL, Beastall GH, Connell JM, Fraser R, McCruden D, Teasdale GM 1985 Body composition, blood pressure and the renin-angiotensin system in acromegaly before and after treatment. J Hypertens Suppl 3:S413-S415
12. Moller J 2003 Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Horm IGF Res 13:55-74
13. Feld S, Hirschberg R 1996 Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev 17:423-480
14. Cain JP, Williams GH, Dluhy RG 1972 Plasma renin activity and aldosterone secretion in patients with acromegaly. J Clin Endocrinol Metab 34:73-81
15. Ogihara T, Hata T, Maruyama A, Mikami H, Nakamaru M, Okada Y, Kumahara Y 1979 Blood pressure response to an angiotensin II antagonist in patients with acromegaly. J Clin Endocrinol Metab 48:159-162
16. Ritchie CM, Sheridan B, Fraser R, Hadden DR, Kennedy AL, Riddell J, Atkinson AB 1990 Studies on the pathogenesis of hypertension in Cushing's disease and acromegaly. Q J Med 76:855-867
17. Karlberg BE, Ottosson AM 1982 Acromegaly and hypertension: role of the renin-angiotensin-aldosterone system. Acta Endocrinol 100:581-587
18. Tripodi G, Valtorta F, Torielli L, Chieregatti E, Salardi S, Trusolino L, Menegon A, Ferrari P, Marchisio PC, Bianchi G 1996 Hypertension-associated point mutations in the adducin α and β subunits affect actin cytoskeleton and ion transport. J Clin Invest 97:2815-2822
19. Bianchi G, Tripodi G, Casari G, Salardi S, Barber BR, Garcia R, Leoni P, Torielli L, Cusi D, Ferrandi M, Pinna LA, Baralles FE, Ferrari P 1994 Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci USA 91:3999-4003
20. Mattson DL, Cowley Jr AW 1993 Kinin actions on renal papillary blood flow and sodium excretion. Hypertension 21:961-965
21. Wang DZ, Chao L, Chao J 1997 Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 29:488-493
22. Staessen JA, Kuznetsova T, Wang JG, Emelianov D, Vlietinck R, Fagard R 1999 M235T angiotensinogen gene polymorphism and cardiovascular renal risk. J Hypertens 17:9-17
23. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig EH, Sharma AM, Hata A, Jeunemaitre X, Lalouel JM 1997 A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99:1786-1797
24. Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, Vlietinck R, Fagard R 1997 The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 15:1579-1592
25. Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, Jeunemaitre X, Corvol P, Pascoe L, Soubrier F 1998 Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 32:198-204
26. Staessen JA, Wang JG, Brand E, Barlassina C, Birkenhager WH, Herrmann SM, Fagard R, Tizzoni L, Bianchi G 2001 Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens 19:1349-1358
27. Davies E, Holloway CD, Ingram MC, Inglis GC, Friel EC, Morrison C, Anderson NH, Fraser R, Connell JM 1999 Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 33:703-707
28. Wang JG, Liu L, Zagato L, Xie J, Fagard R, Jin K, Wang J, Li Y, Bianchi G, Staessen JA, Liu L 2004 Blood pressure in relation to three candidate genes in a Chinese population. J Hypertens 22:937-944
29. Komiya I, Yamada T, Takara M, Asawa T, Shimabukuro M, Nishimori T, Takasu N 2000 Lys(173)Arg and -344T/C variants of CYP11B2 in Japanese patients with low-renin hypertension. Hypertension 35:699-703
30. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P, Troffa C, Zagato L, Bianchi G 1997 Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. Lancet 349:1353-1357
31. Manunta P, Cusi D, Barlassina C, Righetti M, Lanzani C, D'Amico M, Buzzi L, Citterio L, Stella P, Rivera R, Bianchi G 1998 α-Adducin polymorphisms and renal sodium handling in essential hypertensive patients. Kidney Int 53:1471-1478
32. Braun A, Kammerer S, Maier E, Bohme E, Roscher AA 1996 Polymorphisms in the gene for the human B2-bradykinin receptor. New tools in assessing a genetic risk for bradykinin-associated diseases. Immunopharmacology 33:32-35
33. Gainer JV, Brown NJ, Bachvarova M, Bastien L, Maltais I, Marceau F, Bachvarov DR 2000 Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. Am J Hypertens 13:1268-1273
34. Wass JAH 2003 Dynamic testing in the diagnosis and follow-up of patients with acromegaly. J Endocrinol Invest 26:48-53
35. European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053
36. Fallo F, Mulatero P, Vettor R, Scarda A, Della Mea P, Morello F, Veglio F, Williams TA 2004 Bradykinin B2 receptor gene C-58T polymorphism and insulin resistance. A study on obese patients. Horm Metab Res 36:243-246
37. 2 receptor and α-adducin gene polymorphisms. J Clin Endocrinol Metab 87:3337-3343
38. Mulatero P, Rabbia F, di Cella SM, Schiavone D, Plazzotta C, Pascoe L, Veglio F 2001 Angiotensin-converting enzyme and angiotensinogen gene polymorphisms are non-randomly distributed in oral contraceptive-induced hypertension. J Hypertens 19:713-719
39. Mulatero P, Schiavone D, Fallo F, Rabbia F, Pilon C, Chiandussi L, Pascoe L, Veglio F 2000 CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism. Hypertension 35:694-698
40. Storey JD, Tibshirani R 2003 Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100:9440-9445
41. Lin CJ, Mendonca BB, Lucon AM, Guazzelli IC, Nicolau W, Villares SM 1997 Growth hormone receptor messenger ribonucleic acid in normal and pathologic human adrenocortical tissues-an analysis by quantitative polymerase chain reaction technique. J Clin Endocrinol Metab 82:2671-2676
42. Bassett MH, Zhang Y, Clyne C, White PC, Rainey WE 2002 Differential regulation of aldosterone synthase and 11β-hydroxylase transcription by steroidogenic factor-1. J Mol Endocrinol 28:125-135